MarketCap
Facebook
X
TelegramGeschäftsbericht 2023
hinzugefügt 28.02.2024
CymaBay Therapeutics EV 2011-2026 | CBAY
EV Jährlich CymaBay Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.36 B | 936 M | 155 M | 351 M | 105 M | 470 M | 415 M | 48.1 M | 27.9 M | 133 M | -10.5 M | 329 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 3.36 B | -10.5 M | 527 M |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
10.2 B | $ 9.33 | 1.41 % | $ 603 M |  USA |
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
9.45 M | $ 0.87 | -2.13 % | $ 6.4 M | China |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
3.33 B | $ 22.38 | 0.81 % | $ 3.71 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | USA |
 |
Galapagos NV
GLPG
|
82.8 M | $ 28.15 | 1.04 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
11.8 B | $ 8.22 | 3.92 % | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
1.26 B | $ 30.95 | -0.34 % | $ 1.78 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
ImmuCell Corporation
ICCC
|
69.7 M | $ 8.43 | -0.12 % | $ 76.1 M | USA |
 |
InflaRx N.V.
IFRX
|
-2.36 M | $ 1.97 | -0.51 % | $ 152 M | Germany |
 |
Incyte Corporation
INCY
|
18.2 B | $ 98.55 | -0.55 % | $ 19.2 B | USA |
 |
InMed Pharmaceuticals
INM
|
-5.18 M | $ 0.71 | 1.27 % | $ 1.74 M |  Canada |
 |
Innoviva
INVA
|
1.07 B | $ 22.97 | -0.35 % | $ 1.55 B | USA |
 |
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
-4.91 B | $ 104.02 | 2.41 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
Jaguar Health
JAGX
|
57 M | $ 7.34 | -6.79 % | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
944 M | $ 26.68 | 0.02 % | $ 1.44 B | Britain |
 |
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
259 M | $ 1.45 | -2.68 % | $ 235 M | France |
 |
Kamada Ltd.
KMDA
|
252 M | $ 8.16 | 0.68 % | $ 260 M |  Israel |
 |
Krystal Biotech
KRYS
|
8.08 B | $ 260.24 | 0.11 % | $ 7.53 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
141 M | $ 13.58 | 9.34 % | $ 1.8 B |  Australia |
 |
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
2.26 B | $ 220.06 | -2.13 % | $ 4.02 B | USA |
 |
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 2.94 | -1.67 % | $ 4.84 M | Israel |
 |
Liquidia Corporation
LQDA
|
3.04 B | $ 38.41 | 0.67 % | $ 3.31 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
563 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
540 M | $ 4.08 | 0.62 % | $ 436 M | USA |
 |
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.2 M | - | 17.91 % | $ 11.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.64 B | $ 23.15 | 3.49 % | $ 2.95 B | USA |